SJOGREN; Hans Olov

Patent Applications and Registrations

Patent applications and USPTO patent grants for SJOGREN; Hans Olov.The latest application filed is for "psammaplin a for modulating ido expression".

Company Profile

1.2.12

SJOGREN; Hans Olov - Lund SE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Psammaplin A For Modulating Ido Expression App 20210299069 - ERICSSON; Peter ; et al.	2021-09-30
Methods Of Treating A Mammal Suffering From Or Susceptible To An Immune Reaction To Drug Treatment App 20200078453 - Ericsson; Peter ; et al.	2020-03-12
Ex Vivo Methods Of Inducing Ido Expression In Antigen Presenting Cells Using A Compound Selected From The Group Consisting Of Az App 20190201431 - ERICSSON; Peter ; et al.	2019-07-04
Novel Use App 20190192543 - ERICSSON; Peter ; et al.	2019-06-27
Methods Of Inducing Indolamine 2,3 - Dioxygenase (ido) App 20180028621 - Salford; Leif ; et al.	2018-02-01
Methods of inducing indolamine 2,3--dioxygenase (IDO) Grant 9,839,674 - Salford , et al. December 12, 2	2017-12-12
Novel Treatment Method App 20170014499 - Ericsson; Peter ; et al.	2017-01-19
Use Of Zeburaline For The Treatment Of Autoimmune Diseases Or Immune Rejection Of Transplants App 20160068809 - Salford; Leif G. ; et al.	2016-03-10
Composition Comprising At Least Two Compounds Which Induce Indolamine 2,3 - Dioxygenase (IDO), for the Treatment of an Autoimmune Disorder or Suffering from Immune Rejection of Organs App 20150182592 - SALFORD; Leif ; et al.	2015-07-02
Composition Comprising At Least To Compounds Which Induces Indolamine 2,3 - Dioxygenase (ido), For The Treatment Of An Autoimmune Disorder Or Suffering From Immune Rejection Of Organs App 20130309198 - Salford; Leif ; et al.	2013-11-21
Use Of Zeburaline For The Treatment Of Autoimmune Diseases Or Immune Rejection Of Transplants App 20110300142 - Salford; Leif G. ; et al.	2011-12-08
Use of combretastatin A4 and its prodrugs as an immune enhancing therapy Grant 6,773,702 - Pero , et al. August 10, 2	2004-08-10
Use of combretastatin A4 and its prodrugs as an immune enhancing therapy App 20020160973 - Pero, Ronald W. ; et al.	2002-10-31

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.